SPECT/MR debuted this week at the SNMMI annual meeting as a new preclinical hybrid molecular imaging system with promises of higher resolution and lower dose.
SPECT/MR debuted this week as a new preclinical hybrid molecular imaging system with promises of higher resolution and lower dose.
The single photon emission tomography and magnetic resonance system was introduced at the Society of Nuclear Medicine and Molecular Imaging’s 2013 annual meeting in Vancouver, British Columbia.
"We are pioneering simultaneous SPECT and MR imaging technologies now demonstrated in preliminary small animal studies," Benjamin M.W. Tsui, PhD, director of the division of medical imaging physics in the department of radiology, and a professor of radiology, electrical and computer, biomedical engineering, and environmental health sciences at Johns Hopkins University in Baltimore, Md., said in a statement.
Tsui and colleagues have been building the technology for five years with TriFoil Imaging, formerly the preclinical business of Gamma Medica Inc.
“This presents a unique multimodality system that images mice down to a spatial resolution of less than1 mm at high detection efficiency," he said.
SPECT/MR is different from other hybrid modalities because it allows for imaging with biomarkers labeled with a wide range of radionuclides. SPECT/MR has a variety of potential applications, including imaging for cancer, cardiovascular and neurological diseases, thyroid and other endocrine disorders, trauma, inflammation and infection, officials said.
Developers integrated 16 x16 pixel and 1.6 mm pixel pitch cadmium zinc telluride (CZT) solid-state detectors that directly convert incoming photons into electrical signals that are not affected by the static magnetic field. The SPECT insert also houses a "multi-pinhole" collimator that provides both high spatial resolution and capacity for the detection of photons from small animals injected with available or novel nuclear medicine biomarkers that use radionuclides to convey physiological functions of the body.
SPECT/MR also elimates the dose associated with CT and comes at a lower cost than PET/MR, Tsui said. However, the technology is not intended to replace other modalities, but instead to provide biomedical investigators and clinicians more options for optimizing research and patient care, he added. SPECT/MR is expected to be tested in human trials soon.
"We are confident that with sufficient funding we can build a SPECT/MR system for human brain studies in about two years and begin clinical studies by the third year," Tsui said.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.